Novamind Collaborates with Center for Change
Ryan Allway
April 21st, 2021
Psychedelics
TORONTO, ON / ACCESSWIRE / April 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind”), a leading mental health company specialized in psychedelic medicine, has shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP). Novamind collaborated on the study with Center for Change, a specialty psychiatric hospital and leading treatment facility for eating disorders.
In a webinar held by Center for Change on April 8th, 2021, Dr. Reid Robison, Novamind’s Chief Medical Officer, discussed early findings from the two studies for eating disorders. The collaboration with Center for Change examines the novel use of Novamind’s ketamine-assisted psychotherapy (“KAP”) protocols for the treatment of eating disorders. There are no FDA-approved medication options currently available for individuals suffering from Anorexia Nervosa, an often-debilitating mental health condition.
“Novamind is dedicated to researching, developing and delivering new therapeutic protocols to answer unmet needs in mental healthcare,” said Dr. Robison, who also serves as Medical Director for Center for Change. “Our treatment protocols are designed to improve patient outcomes, and we’re proud that renowned facilities like Center for Change recognize that we can provide new options for individuals struggling with eating disorders.”
Novamind offers its clients access to several KAP protocols through Cedar Psychiatry, its wholly owned network of psychiatry clinics. Specialized KAP protocols currently available at Cedar Psychiatry include Emotion-Focused Ketamine-Assisted Psychotherapy and Group Ketamine-Assisted Psychotherapy. Cedar Psychiatry has administered over 7,000 ketamine treatments since 2016 and is undergoing an expansion of its clinic network in the United States.
“Novamind’s psychedelic protocols are informed by the expertise gained from our operating clinics, as well as collaborating with leading medical institutions. We’re pleased to work with Center for Change to advance innovation in mental healthcare,” said Yaron Conforti, CEO and Director of Novamind.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
About Center for Change
Center for Change was founded on October 28th, 1994, by a team of psychologists and a physician with a long history together. From those first days, Center for Change began to design the current facility and develop its core treatment programs. A handpicked team of experts forms the backbone of what we do, and they are committed to helping each person get back their life and restore a sense of freedom that may have been absent for far too long.
The Center is licensed with the State of Utah as a Specialty Psychiatric Hospital, and in April 1998, Center for Change received accreditation from The Joint Commission. This accreditation is limited to top organizations delivering high levels of patient service, reducing patient risk and creating an environment for continuous improvement. The Joint Commission has recognized Center for Change for its high standards of patient care and commitment to ongoing education.
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: bill@novamind.ca
Center for Change
Tamara Bingham Noyes, Director of Business Development
Telephone: +1 (888) 224 8250 ext. 267
Email: Tamara.Noyes@uhsinc.com
Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
ManifestSeven (M7), formerly known as MJIC, is the first integrated omnichannel platform for legal cannabis, merging compliant distribution with a retail superhighway.
GreenStar Biosciences Corp. (CSE: GSTR) is a growth oriented technology & services company that provides real estate, financial, management, IP & branding support to licensed cannabis businesses as well as partnering and investing in innovative technologies and other emerging businesses.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
